---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-010094"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2022-03-14T23:59:59+00:00"
generated_at: "2026-06-26T23:26:50.314105+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma reports FY2021 net loss $19.3M, cash $53.4M; rNAPc2 data due late March 2022

## Summary
- Net loss $19.3M ($1.39/share) vs $9.7M ($2.07/share) in FY2020; total operating expenses $19.3M.
- Cash and equivalents $53.4M at Dec 31, 2021, up from $49.1M; runway through mid-2023.
- R&D expenses $13.8M (up from $5.0M) driven by rNAPc2 trial; FY2022 R&D expected similar.
- Topline data from Phase 2b ASPEN-COVID-19 trial for rNAPc2 anticipated last week of March 2022.
- Gencaro paper published in Heart Rhythm O2; company evaluating PRECISION-AF trial feasibility.

## SEC filing metadata
- accession: 0001564590-22-010094
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2022-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000156459022010094/0001564590-22-010094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000156459022010094/abio-8k_20220314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-010094
- JSON: https://secwatch.observer/filing/0001564590-22-010094.json
- Plain text: https://secwatch.observer/filing/0001564590-22-010094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.